The impact of EPA and DHA on ceramide lipotoxicity in the metabolic syndrome. Issue 8 (28th April 2021)

• Record Type: Journal Article
• Authors: Walchuk, Chelsey; Wang, Yidi; Suh, Miyoung
• Is Part Of: British journal of nutrition. Volume 125:Issue 8(2021)
• Page Start: 863
• Page End: 875
• Publication Date: 2021-04-28
• Subjects: Ceramide, -- Lipotoxicity, -- Metabolic syndrome, -- High-fat diet, -- n-3 Long-chain PUFA, -- EPA, -- DHA; Nutrition -- Periodicals; 572.4
• DOI: 10.1017/S0007114520003177
• Languages: English
• ISSNs: 0007-1145

Abstract

Abstract: The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors including obesity, insulin resistance (IR) and dyslipidaemia. Consumption of a high-fat diet (HFD) enriched in SFA leads to the accumulation of ceramide (Cer), the central molecule in sphingolipid metabolism. Elevations in plasma and tissue Cer are found in obese individuals, and there is evidence to suggest that Cer lipotoxicity contributes to the MetS. EPA and DHA have shown to improve MetS parameters including IR, inflammation and hypertriacylglycerolaemia; however, whether these improvements are related to Cer is currently unknown. This review examines the potential of EPA and DHA to improve Cer lipotoxicity and MetS parameters including IR, inflammation and dyslipidaemia in vitro and in vivo . Current evidence from cell culture and animal studies indicates that EPA and DHA attenuate palmitate- or HFD-induced Cer lipotoxicity and IR, whereas evidence in humans is greatly lacking. Overall, there is intriguing potential for EPA and DHA to improve Cer lipotoxicity and related MetS parameters, but more research is warranted. Abstract :